Quinazolinone and Phthalazinone Inhibitors of the HDAC6/Ubiquitin Protein–Protein Interaction
ChemBioChem · 26.06.2026 · 27 (12)
DOI: 10.1002/cbic.70423 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, online erschienen am 24.06.2026. Verfasst von Sydney Gordon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA. Hauptthemen laut MEDLINE: Histone Deacetylase 6, Histone Deacetylase Inhibitors, Quinazolinones, Ubiquitin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Histone deacetylase 6 (HDAC6) is a class IIb histone deacetylase that regulates diverse cytosolic acetylation through its two catalytic deacetylase domains and a C‐terminal zinc finger ubiquitin‐binding domain (ZnF‐UBD). This ZnF‐UBD mediates key protein–protein interactions (PPIs) that couple deacetylation and ubiquitin‐dependent degradation. While most HDAC6 inhibitors target the catalytic domains, the ZnF‐UBD represents an underexplored target. Here, we validate previously reported small‐molecule inhibitors of the HDAC6 ZnF‐UBD/ubiquitin interaction and describe novel N‐alkyl moieties based on quinazolinone and phthalazinone scaffolds. Starting from known quinazolinone and phthalazinone scaffolds, a literature and modeling‐guided scaffold hop revealed potential for an extended phthalazinone series. Results obtained both in fluorescence polarization (FP) and differential scanning fluorimetry (DSF) confirm this hypothesis. Additionally, late‐stage diversification yields compounds with improved predicted physicochemical properties. Finally, machine‐learning‐based co‐folding affinity predictions correlate with experimental IC 50 rank order, highlighting their utility in PPI inhibitor design. These studies continue expanding the chemical space of HDAC6 ZnF‐UBD inhibitors and build upon existing foundations for future therapeutic and mechanistic exploration of HDAC6–ubiquitin signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA.
- Department of Cancer Biology, University of Pennsylvania, Philadelphia, PA, USA.
- Epigenetics Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
ORCID-Profile: Jordi C J Hintzen, George M Burslem
Förderung
- NIGMS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Gordon, S., Hintzen, J. C. J., Dilones, S., Keen, B., Crawford, C. E. W., & Burslem, G. M. (2026). Quinazolinone and Phthalazinone Inhibitors of the HDAC6/Ubiquitin Protein–Protein Interaction. ChemBioChem, 27(12). https://doi.org/10.1002/cbic.70423
Vancouver
Gordon S, Hintzen JCJ, Dilones S, Keen B, Crawford CEW, Burslem GM. Quinazolinone and Phthalazinone Inhibitors of the HDAC6/Ubiquitin Protein–Protein Interaction. ChemBioChem. 2026;27(12). doi:10.1002/cbic.70423
BibTeX
@article{Gordon2026,
author = {Gordon, Sydney and Hintzen, Jordi C J and Dilones, Sebastian and Keen, Brockton and Crawford, Callie E W and Burslem, George M},
title = {Quinazolinone and Phthalazinone Inhibitors of the HDAC6/Ubiquitin Protein–Protein Interaction},
journal = {ChemBioChem},
year = {2026},
volume = {27},
number = {12},
doi = {10.1002/cbic.70423}
}
EUVIMED